Is ATNM or OBSV more profitable?

Actinium Pharmaceuticals' return on equity of -100.85% beat ObsEva's return on equity. Company Net Margins Return on Equity Return on Assets Actinium Pharmaceuticals N/A -100.85% -47.89% ObsEva N/A -416.36% -92.01%

Do analysts rate KYNB or OBSV?

Kyntra Bio presently has a consensus target price of $30.00, indicating a potential upside of 293.18%. Given Kyntra Bio's stronger consensus rating and higher possible upside, analysts clearly believe Kyntra Bio is more favorable than ObsEva. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kyntra Bio 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50 ObsEva 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation and earnings, KYNB or OBSV?

Kyntra Bio has higher revenue and earnings than ObsEva. ObsEva is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kyntra Bio $6.44M 4.80 $183.45M $40.46 0.19 ObsEva N/A N/A -$58.38M -$0.92 N/A

Is KYNB or OBSV more profitable?

Kyntra Bio has a net margin of 2,199.13% compared to ObsEva's net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat ObsEva's return on equity. Company Net Margins Return on Equity Return on Assets Kyntra Bio 2,199.13% N/A -36.71% ObsEva N/A -416.36% -92.01%

Do analysts recommend LSTA or OBSV?

Lisata Therapeutics currently has a consensus price target of $15.00, indicating a potential upside of 350.45%. Given Lisata Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Lisata Therapeutics is more favorable than ObsEva. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lisata Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 ObsEva 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is LSTA or OBSV more profitable?

Lisata Therapeutics' return on equity of -103.54% beat ObsEva's return on equity. Company Net Margins Return on Equity Return on Assets Lisata Therapeutics N/A -103.54% -83.08% ObsEva N/A -416.36% -92.01%

Is GRDX or OBSV more profitable?

Entero Therapeutics' return on equity of -49.81% beat ObsEva's return on equity. Company Net Margins Return on Equity Return on Assets Entero Therapeutics N/A -49.81% -11.02% ObsEva N/A -416.36% -92.01%

Do analysts recommend BCTX or OBSV?

Given ObsEva's higher probable upside, analysts clearly believe ObsEva is more favorable than Briacell Therap. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Briacell Therap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ObsEva 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable valuation & earnings, BCTX or OBSV?

Briacell Therap is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Briacell Therap N/A N/A -$26.31M -$7.92 N/A ObsEva N/A N/A -$58.38M -$0.92 N/A

Is BCTX or OBSV more profitable?

Briacell Therap's return on equity of -153.53% beat ObsEva's return on equity. Company Net Margins Return on Equity Return on Assets Briacell Therap N/A -153.53% -129.26% ObsEva N/A -416.36% -92.01%

ObsEva (OBSV) Competitors

Compare

OBSV vs. ATNM, KYNB, LSTA, GRDX, and BCTX

Should you buy ObsEva stock or one of its competitors? MarketBeat compares ObsEva with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ObsEva include Actinium Pharmaceuticals (ATNM), Kyntra Bio (KYNB), Lisata Therapeutics (LSTA), Entero Therapeutics (GRDX), and Briacell Therap (BCTX). These companies are all part of the "pharmaceutical products" industry.

How does ObsEva compare to Actinium Pharmaceuticals?

Actinium Pharmaceuticals (NYSE:ATNM) and ObsEva (NASDAQ:OBSV) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings, media sentiment and valuation.

In the previous week, Actinium Pharmaceuticals' average media sentiment score of 0.00 equaled ObsEva'saverage media sentiment score.

Company	Overall Sentiment
Actinium Pharmaceuticals	Neutral
ObsEva	Neutral

Actinium Pharmaceuticals' return on equity of -100.85% beat ObsEva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%
ObsEva	N/A	-416.36%	-92.01%

Actinium Pharmaceuticals has a beta of -0.02, indicating that its share price is 102% less volatile than the broader market. Comparatively, ObsEva has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market.

Actinium Pharmaceuticals presently has a consensus price target of $5.00, suggesting a potential upside of 409.68%. Given Actinium Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Actinium Pharmaceuticals is more favorable than ObsEva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
ObsEva	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

27.5% of Actinium Pharmaceuticals shares are held by institutional investors. Comparatively, 17.5% of ObsEva shares are held by institutional investors. 0.6% of Actinium Pharmaceuticals shares are held by insiders. Comparatively, 14.4% of ObsEva shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Actinium Pharmaceuticals has higher revenue and earnings than ObsEva. Actinium Pharmaceuticals is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actinium Pharmaceuticals	$90K	341.99	-$48.82M	-$0.75	N/A
ObsEva	N/A	N/A	-$58.38M	-$0.92	N/A

Summary

Actinium Pharmaceuticals beats ObsEva on 9 of the 12 factors compared between the two stocks.

How does ObsEva compare to Kyntra Bio?

Kyntra Bio (NASDAQ:KYNB) and ObsEva (NASDAQ:OBSV) are both small-cap pharmaceutical preparations industry companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

Kyntra Bio has a beta of 0.96, meaning that its stock price is 4% less volatile than the broader market. Comparatively, ObsEva has a beta of 0.68, meaning that its stock price is 32% less volatile than the broader market.

Kyntra Bio has a net margin of 2,199.13% compared to ObsEva's net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat ObsEva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kyntra Bio	2,199.13%	N/A	-36.71%
ObsEva	N/A	-416.36%	-92.01%

Kyntra Bio presently has a consensus target price of $30.00, indicating a potential upside of 293.18%. Given Kyntra Bio's stronger consensus rating and higher possible upside, analysts clearly believe Kyntra Bio is more favorable than ObsEva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
ObsEva	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Kyntra Bio has higher revenue and earnings than ObsEva. ObsEva is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyntra Bio	$6.44M	4.80	$183.45M	$40.46	0.19
ObsEva	N/A	N/A	-$58.38M	-$0.92	N/A

72.7% of Kyntra Bio shares are owned by institutional investors. Comparatively, 17.5% of ObsEva shares are owned by institutional investors. 4.2% of Kyntra Bio shares are owned by company insiders. Comparatively, 14.4% of ObsEva shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Kyntra Bio had 1 more articles in the media than ObsEva. MarketBeat recorded 1 mentions for Kyntra Bio and 0 mentions for ObsEva. Kyntra Bio's average media sentiment score of 0.00 equaled ObsEva'saverage media sentiment score.

Company	Overall Sentiment
Kyntra Bio	Neutral
ObsEva	Neutral

Summary

Kyntra Bio beats ObsEva on 14 of the 15 factors compared between the two stocks.

How does ObsEva compare to Lisata Therapeutics?

Lisata Therapeutics (NASDAQ:LSTA) and ObsEva (NASDAQ:OBSV) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk, media sentiment and valuation.

Lisata Therapeutics currently has a consensus price target of $15.00, indicating a potential upside of 350.45%. Given Lisata Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Lisata Therapeutics is more favorable than ObsEva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lisata Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
ObsEva	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Lisata Therapeutics has higher revenue and earnings than ObsEva. Lisata Therapeutics is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lisata Therapeutics	$170K	178.45	-$16.59M	-$1.86	N/A
ObsEva	N/A	N/A	-$58.38M	-$0.92	N/A

Lisata Therapeutics' return on equity of -103.54% beat ObsEva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lisata Therapeutics	N/A	-103.54%	-83.08%
ObsEva	N/A	-416.36%	-92.01%

Lisata Therapeutics has a beta of 0.79, suggesting that its stock price is 21% less volatile than the broader market. Comparatively, ObsEva has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market.

8.9% of Lisata Therapeutics shares are held by institutional investors. Comparatively, 17.5% of ObsEva shares are held by institutional investors. 9.6% of Lisata Therapeutics shares are held by company insiders. Comparatively, 14.4% of ObsEva shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Lisata Therapeutics' average media sentiment score of 0.00 equaled ObsEva'saverage media sentiment score.

Company	Overall Sentiment
Lisata Therapeutics	Neutral
ObsEva	Neutral

Summary

Lisata Therapeutics beats ObsEva on 7 of the 11 factors compared between the two stocks.

How does ObsEva compare to Entero Therapeutics?

Entero Therapeutics (NASDAQ:GRDX) and ObsEva (NASDAQ:OBSV) are both small-cap pharmaceutical preparations industry companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, media sentiment, valuation, profitability and analyst recommendations.

Entero Therapeutics' return on equity of -49.81% beat ObsEva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entero Therapeutics	N/A	-49.81%	-11.02%
ObsEva	N/A	-416.36%	-92.01%

In the previous week, Entero Therapeutics' average media sentiment score of 0.00 equaled ObsEva'saverage media sentiment score.

Company	Overall Sentiment
Entero Therapeutics	Neutral
ObsEva	Neutral

12.3% of Entero Therapeutics shares are held by institutional investors. Comparatively, 17.5% of ObsEva shares are held by institutional investors. 0.8% of Entero Therapeutics shares are held by company insiders. Comparatively, 14.4% of ObsEva shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Entero Therapeutics has a beta of 1.81, indicating that its share price is 81% more volatile than the broader market. Comparatively, ObsEva has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market.

Entero Therapeutics has higher revenue and earnings than ObsEva. Entero Therapeutics is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entero Therapeutics	$40K	731.50	-$6.39M	-$1.88	N/A
ObsEva	N/A	N/A	-$58.38M	-$0.92	N/A

Summary

Entero Therapeutics beats ObsEva on 5 of the 9 factors compared between the two stocks.

How does ObsEva compare to Briacell Therap?

Briacell Therap (NASDAQ:BCTX) and ObsEva (NASDAQ:OBSV) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.

Briacell Therap has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market. Comparatively, ObsEva has a beta of 0.68, suggesting that its share price is 32% less volatile than the broader market.

15.4% of Briacell Therap shares are held by institutional investors. Comparatively, 17.5% of ObsEva shares are held by institutional investors. 0.7% of Briacell Therap shares are held by insiders. Comparatively, 14.4% of ObsEva shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Briacell Therap's average media sentiment score of 0.00 equaled ObsEva'saverage media sentiment score.

Company	Overall Sentiment
Briacell Therap	Neutral
ObsEva	Neutral

Given ObsEva's higher probable upside, analysts clearly believe ObsEva is more favorable than Briacell Therap.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ObsEva	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Briacell Therap's return on equity of -153.53% beat ObsEva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Briacell Therap	N/A	-153.53%	-129.26%
ObsEva	N/A	-416.36%	-92.01%

Briacell Therap is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Briacell Therap	N/A	N/A	-$26.31M	-$7.92	N/A
ObsEva	N/A	N/A	-$58.38M	-$0.92	N/A

Summary

ObsEva beats Briacell Therap on 6 of the 10 factors compared between the two stocks.

Get ObsEva News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OBSV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OBSV vs. The Competition

Export

Metric	ObsEva	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$7.94M	$791.45M	$7.16B	$12.48B
Dividend Yield	N/A	4.84%	2.66%	6.52%
P/E Ratio	0.00	1.66	28.02	24.70
Price / Sales	N/A	127.11	540.37	99.49
Price / Cash	N/A	20.06	49.26	57.09
Price / Book	N/A	8.17	10.96	6.46
Net Income	-$58.38M	-$3.71M	$3.57B	$337.01M

ObsEva Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OBSV ObsEva	N/A	N/A	N/A	N/A	$7.94M	N/A	N/A	50
ATNM Actinium Pharmaceuticals	2.0098 of 5 stars	$0.99 +0.5%	$5.00 +407.6%	-31.9%	$30.90M	$90K	N/A	30
KYNB Kyntra Bio	3.6732 of 5 stars	$7.62 +1.0%	$30.00 +293.6%	N/A	$30.87M	$6.44M	0.19	570
LSTA Lisata Therapeutics	2.2797 of 5 stars	$3.39 +0.8%	$15.00 +343.0%	+26.1%	$30.85M	$170K	N/A	30
GRDX Entero Therapeutics	N/A	$4.63 -1.4%	N/A	N/A	$30.76M	$40K	N/A	9	Positive News Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OBSV) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ObsEva (OBSV) Competitors

OBSV vs. ATNM, KYNB, LSTA, GRDX, and BCTX

How does ObsEva compare to Actinium Pharmaceuticals?

Summary

How does ObsEva compare to Kyntra Bio?

Summary

How does ObsEva compare to Lisata Therapeutics?

Summary

How does ObsEva compare to Entero Therapeutics?

Summary

How does ObsEva compare to Briacell Therap?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OBSV vs. The Competition

ObsEva Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ObsEva (OBSV) Competitors

OBSV vs. ATNM, KYNB, LSTA, GRDX, and BCTX

How does ObsEva compare to Actinium Pharmaceuticals?

Does the media prefer ATNM or OBSV?

Is ATNM or OBSV more profitable?

Which has more risk and volatility, ATNM or OBSV?

Do analysts recommend ATNM or OBSV?

Do institutionals and insiders have more ownership in ATNM or OBSV?

Which has higher earnings and valuation, ATNM or OBSV?

Summary

How does ObsEva compare to Kyntra Bio?

Which has more risk and volatility, KYNB or OBSV?

Is KYNB or OBSV more profitable?

Do analysts rate KYNB or OBSV?

Which has higher valuation and earnings, KYNB or OBSV?

Do insiders & institutionals hold more shares of KYNB or OBSV?

Does the media prefer KYNB or OBSV?

Summary

How does ObsEva compare to Lisata Therapeutics?

Do analysts recommend LSTA or OBSV?

Which has preferable valuation & earnings, LSTA or OBSV?

Is LSTA or OBSV more profitable?

Which has more risk and volatility, LSTA or OBSV?

Do insiders and institutionals hold more shares of LSTA or OBSV?

Does the media prefer LSTA or OBSV?

Summary

How does ObsEva compare to Entero Therapeutics?

Is GRDX or OBSV more profitable?

Does the media refer more to GRDX or OBSV?

Do insiders and institutionals believe in GRDX or OBSV?

Which has more volatility & risk, GRDX or OBSV?

Which has better valuation & earnings, GRDX or OBSV?

Summary

How does ObsEva compare to Briacell Therap?

Which has more volatility & risk, BCTX or OBSV?

Do insiders & institutionals have more ownership in BCTX or OBSV?

Does the media refer more to BCTX or OBSV?

Do analysts recommend BCTX or OBSV?

Is BCTX or OBSV more profitable?

Which has preferable valuation & earnings, BCTX or OBSV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OBSV vs. The Competition

ObsEva Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools